About Anika Therapeutics (NASDAQ:ANIK)
Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. has a strategic collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst to develop a therapy for rheumatoid arthritis. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ANIK
CUSIP03525510
Phone781-457-9000
Debt
Debt-to-Equity RatioN/A
Current Ratio15.79%
Quick Ratio14.10%
Price-To-Earnings
Trailing P/E Ratio22.75
Forward P/E Ratio28.38
P/E Growth2.85
Sales & Book Value
Annual Sales$113.42 million
Price / Sales5.79
Cash Flow$2.2928 per share
Price / Cash19.43
Book Value$17.97 per share
Price / Book2.48
Profitability
EPS (Most Recent Fiscal Year)$1.96
Net Income$31.81 million
Net Margins28.05%
Return on Equity11.91%
Return on Assets11.05%
Miscellaneous
Employees123
Outstanding Shares14,740,000
Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions
What is Anika Therapeutics' stock symbol?
Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."
How were Anika Therapeutics' earnings last quarter?
Anika Therapeutics Inc. (NASDAQ:ANIK) announced its earnings results on Wednesday, February, 21st. The biotechnology company reported $0.38 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.41 by $0.03. The biotechnology company earned $29.39 million during the quarter, compared to the consensus estimate of $29.85 million. Anika Therapeutics had a net margin of 28.05% and a return on equity of 11.91%. The company's revenue was up 2.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.54 EPS. View Anika Therapeutics' Earnings History.
When is Anika Therapeutics' next earnings date?
What price target have analysts set for ANIK?
3 brokerages have issued 12-month target prices for Anika Therapeutics' shares. Their forecasts range from $57.00 to $68.00. On average, they expect Anika Therapeutics' stock price to reach $62.50 in the next twelve months. View Analyst Ratings for Anika Therapeutics.
Who are some of Anika Therapeutics' key competitors?
Some companies that are related to Anika Therapeutics include Merit Medical Systems (MMSI), NovoCure (NVCR), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), OraSure Technologies (OSUR), Glaukos (GKOS), Luminex (LMNX), K2M Group (KTWO), MiMedx Group (MDXG), CryoLife (CRY), LeMaitre Vascular (LMAT) and Cardiovascular Systems (CSII).
Who are Anika Therapeutics' key executives?
Anika Therapeutics' management team includes the folowing people:
- Ms. Sylvia Cheung, CFO, Treasurer & Sec. (Age 43)
- Dr. Edward S. Ahn Ph.D., Chief Technology & Strategy Officer (Age 46)
- Mr. Richard Hague, Chief Commercial Officer (Age 58)
- Mr. Joseph G. Darling, CEO, Pres & Director (Age 60)
- Mr. Thomas M. Finnerty, Chief HR Officer
Has Anika Therapeutics been receiving favorable news coverage?
Media stories about ANIK stock have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Anika Therapeutics earned a news sentiment score of 0.18 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 46.30 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Anika Therapeutics' major shareholders?
Anika Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include
SHERWOOD CHARLES H
(5.15%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Jeffery S Thompson, Joseph I Bower and Richard Hague. View Institutional Ownership Trends for Anika Therapeutics.
How do I buy shares of Anika Therapeutics?
Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Anika Therapeutics' stock price today?
One share of ANIK stock can currently be purchased for approximately $45.06.
How big of a company is Anika Therapeutics?
Anika Therapeutics has a market capitalization of $660.73 million and generates $113.42 million in revenue each year. The biotechnology company earns $31.81 million in net income (profit) each year or $1.96 on an earnings per share basis. Anika Therapeutics employs 123 workers across the globe.
How can I contact Anika Therapeutics?
Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]
MarketBeat Community Rating for Anika Therapeutics (ANIK)
MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe ANIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIK will underperform the S&P 500 over the long term. You may vote once every thirty days.
Anika Therapeutics (NASDAQ:ANIK) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Anika Therapeutics in the last 12 months. Their average twelve-month price target is $62.50, suggesting that the stock has a possible upside of 40.29%. The high price target for ANIK is $68.00 and the low price target for ANIK is $57.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $62.50 | $62.50 | $62.50 | $57.00 |
| Price Target Upside: | 40.29% upside | 8.30% upside | 5.25% upside | 3.92% upside |
Anika Therapeutics (NASDAQ:ANIK) Consensus Price Target History
Anika Therapeutics (NASDAQ:ANIK) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Anika Therapeutics (NASDAQ:ANIK) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Anika Therapeutics (NASDAQ ANIK) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.08%
Institutional Ownership Percentage: 84.01%
Anika Therapeutics (NASDAQ ANIK) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/30/2017 | Richard Hague | Insider | Sell | 5,250 | $54.48 | $286,020.00 | |  |
| 10/23/2017 | Charles H Sherwood | CEO | Sell | 22,228 | $60.06 | $1,335,013.68 | 158,297 | |
| 10/20/2017 | Charles H Sherwood | CEO | Sell | 5,991 | $60.04 | $359,699.64 | 158,297 | |
| 10/16/2017 | Charles H Sherwood | CEO | Sell | 3,293 | $60.04 | $197,711.72 | | |
| 10/13/2017 | Charles H Sherwood | CEO | Sell | 7,124 | $60.08 | $428,009.92 | | |
| 7/27/2017 | Charles H Sherwood | CEO | Sell | 63,799 | $50.79 | $3,240,351.21 | 174,705 | |
| 7/5/2017 | Charles H Sherwood | CEO | Sell | 14,201 | $50.03 | $710,476.03 | 246,740 | |
| 5/22/2017 | Jeffery S Thompson | Director | Sell | 10,725 | $47.39 | $508,257.75 | 15,845 | |
| 11/9/2016 | Joseph I Bower | Director | Sell | 540 | $43.39 | $23,430.60 | 38,513 | |
| 2/25/2016 | Raymond J Land | Director | Sell | 2,695 | $43.62 | $117,555.90 | 14,165 | |
| 2/27/2015 | Raymond J Land | Director | Sell | 4,621 | $39.49 | $182,483.29 | | |
| 5/1/2014 | Charles H Sherwood | CEO | Sell | 83,780 | $44.32 | $3,713,129.60 | | |
| 2/28/2014 | Charles H Sherwood | CEO | Sell | 200,000 | $41.70 | $8,340,000.00 | | |
| 8/22/2013 | John C Moran | Director | Sell | 5,000 | $24.35 | $121,750.00 | | |
| 8/8/2013 | Steve E Wheeler | Director | Sell | 26,984 | $23.61 | $637,092.24 | | |
| 8/7/2013 | Steve E Wheeler | Director | Sell | 11,016 | $27.01 | $297,542.16 | | |
| 8/6/2013 | Farmaceutici S.P.A. Fidia | Major Shareholder | Sell | 1,270,000 | $24.52 | $31,140,400.00 | | |
| 7/15/2013 | Charles H Sherwood | CEO | Sell | 75,000 | $20.11 | $1,508,250.00 | | |
| 7/9/2013 | Charles H Sherwood | CEO | Sell | 49,185 | $18.06 | $888,281.10 | | |
| 7/5/2013 | Charles H Sherwood | CEO | Sell | 34,662 | $18.01 | $624,262.62 | | |
| 6/19/2013 | Charles H Sherwood | CEO | Sell | 1,847 | $18.00 | $33,246.00 | | |
(Data available from 1/1/2013 forward)
Anika Therapeutics (NASDAQ ANIK) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Anika Therapeutics (ANIK) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 25 at 4:28 AM |
 | Anika to Present at the 2018 Deutsche Bank Health Care Conference on May 8, 2018
finance.yahoo.com - April 24 at 5:24 PM |
| Anika Therapeutics (ANIK) Downgraded to Sell at BidaskClub
www.americanbankingnews.com - April 20 at 11:54 AM |
| Anika to Issue First-Quarter 2018 Financial Results and Business Highlights on Wednesday, May 2
finance.yahoo.com - April 18 at 5:32 PM |
| Anika Therapeutics Inc (ANIK) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - April 12 at 11:20 PM |
| Anika Therapeutics (ANIK) Downgraded by ValuEngine
www.americanbankingnews.com - April 12 at 10:19 PM |
| Anika Therapeutics (ANIK) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 12 at 7:25 PM |
| Anika Announces Plans to Showcase HYALOFAST Hyaluronic Acid-Based Scaffold at the 2018 World Congress of the International Cartilage Repair Society
finance.yahoo.com - April 6 at 8:46 AM |
| Brokerages Anticipate Anika Therapeutics Inc (ANIK) to Post $0.25 Earnings Per Share
www.americanbankingnews.com - March 30 at 3:24 AM |
| With A -2.25% Earnings Drop, Is Anika Therapeutics Inc’s (FRA:AKP) A Concern?
finance.yahoo.com - March 29 at 8:44 AM |
| Anika Therapeutics Inc (ANIK) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 26 at 1:32 AM |
| Edited Transcript of ANIK earnings conference call or presentation 22-Feb-18 2:00pm GMT
finance.yahoo.com - March 22 at 5:24 PM |
| Brokerages Set $68.00 Target Price for Anika Therapeutics Inc (ANIK)
www.americanbankingnews.com - March 20 at 1:18 AM |
 | Director's Letter Micro Cap Summary - March 2018
seekingalpha.com - March 15 at 5:53 PM |
| Anika to Showcase Commercial and Pipeline Portfolio at 2018 AAOS Annual Meeting
finance.yahoo.com - March 14 at 8:58 AM |
| Critical Review: Anika Therapeutics (ANIK) and Onconova Therapeutics (ONTX)
www.americanbankingnews.com - March 10 at 12:17 PM |
 | Joseph Darling Named CEO and Director of Anika Therapeutics - GlobeNewswire (press release)
globenewswire.com - March 6 at 8:32 AM |
| Anika to Showcase Commercial and Pipeline Portfolio at 2018 AAOS Annual Meeting - GlobeNewswire (press release)
globenewswire.com - March 6 at 8:32 AM |
| Analysts Set $68.00 Price Target for Anika Therapeutics Inc (ANIK)
www.americanbankingnews.com - March 5 at 5:14 AM |
| Anika Therapeutics Inc (ANIK) Holdings Lifted by Bbva Compass Bancshares Inc.
www.americanbankingnews.com - March 1 at 4:56 AM |
| First Analysis Comments on Anika Therapeutics Inc's FY2019 Earnings (ANIK)
www.americanbankingnews.com - February 28 at 3:18 PM |
| First Analysis Brokers Decrease Earnings Estimates for Anika Therapeutics Inc (ANIK)
www.americanbankingnews.com - February 27 at 8:38 AM |
| New Strong Sell Stocks for February 27th
finance.yahoo.com - February 27 at 8:37 AM |
| Anika Therapeutics Inc (ANIK) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 27 at 8:37 AM |
| Anika Therapeutics (ANIK) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - February 26 at 5:24 PM |
| Equities Analysts Issue Forecasts for Anika Therapeutics Inc's Q1 2018 Earnings (ANIK)
www.americanbankingnews.com - February 26 at 3:18 AM |
| Anika Therapeutics (ANIK) Lowered to Hold at BidaskClub
www.americanbankingnews.com - February 24 at 3:52 PM |
| Anika Therapeutics' (ANIK) CEO Charles Sherwood on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - February 24 at 8:30 AM |
 | Anika Therapeutics (NASDAQ:ANIK) Shares Stunted By Increased ... - Benzinga
www.benzinga.com - February 24 at 8:30 AM |
| Kamada (KMDA) and Anika Therapeutics (ANIK) Critical Survey
www.americanbankingnews.com - February 24 at 1:06 AM |
| Anika Therapeutics Shares Stunted By Increased Investment, Barrington Says In Downgrade
finance.yahoo.com - February 23 at 5:42 PM |
| Anika Therapeutics (ANIK) Rating Lowered to Market Perform at Barrington Research
www.americanbankingnews.com - February 23 at 4:28 PM |
| Anika Therapeutics Inc. 2017 Q4 - Results - Earnings Call Slides
seekingalpha.com - February 22 at 5:27 PM |
| Anika Therapeutics (ANIK) Releases Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - February 22 at 3:26 PM |
| Anika Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 21 at 5:17 PM |
| When Should You Buy Anika Therapeutics Inc (NASDAQ:ANIK)?
finance.yahoo.com - February 21 at 5:17 PM |
| Zacks: Anika Therapeutics Inc (ANIK) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - February 18 at 3:14 AM |
| Anika Therapeutics (ANIK) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - February 14 at 4:32 AM |
| Anika to Issue Fourth-Quarter 2017 Financial Results and Business Highlights on Wednesday, February 21
finance.yahoo.com - February 8 at 8:21 AM |
| Anika Therapeutics (ANIK) to Release Earnings on Tuesday
www.americanbankingnews.com - February 6 at 3:12 AM |
| Analysts Set $62.50 Target Price for Anika Therapeutics Inc (ANIK)
www.americanbankingnews.com - February 3 at 3:26 AM |
| Anika Therapeutics Announces Strategic Collaboration with the Institute of Integrative Biology at the University of Liverpool to Develop an Innovative Therapy for Osteoarthritis
finance.yahoo.com - February 2 at 9:46 AM |
| First Analysis Upgrades Anika Therapeutics (ANIK) to "Overweight"
www.americanbankingnews.com - January 28 at 6:36 PM |
| Anika Therapeutics (ANIK) Lifted to Buy at BidaskClub
www.americanbankingnews.com - January 27 at 10:16 AM |
| Sidoti Initiates Coverage on Anika Therapeutics (ANIK)
www.americanbankingnews.com - January 26 at 4:54 PM |
| First Analysis Weighs in on Anika Therapeutics Inc's Q4 2017 Earnings (ANIK)
www.americanbankingnews.com - January 26 at 6:46 AM |
| Anika Therapeutics Expands Strategic Collaboration with the Institute for Applied Life Sciences (IALS) at the University of Massachusetts Amherst to Develop Innovative Therapy for Rheumatoid Arthritis
finance.yahoo.com - January 25 at 9:46 AM |
| First Analysis Weighs in on Anika Therapeutics Inc's FY2017 Earnings (ANIK)
www.americanbankingnews.com - January 25 at 7:58 AM |
| Recent Analysis Shows Darling Ingredients, Principal Financial Group, UGI, Cass Information, WD-40, and Anika Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - January 22 at 9:22 AM |
| Analysts Set $57.00 Price Target for Anika Therapeutics Inc. (ANIK)
www.americanbankingnews.com - January 19 at 3:58 AM |
Anika Therapeutics (NASDAQ:ANIK) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Anika Therapeutics (NASDAQ:ANIK) Income Statement, Balance Sheet and Cash Flow Statement
Anika Therapeutics (NASDAQ ANIK) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
